Intergroup Randomized Phase II Four Arm Study In Patients = 60 With Previously Untreated Mantle Cell Lymphoma
Posted Date: May 15, 2019
- Investigator: Tahir Latif
- Type of Study: Drug
The purpose of this study is two-fold and has two steps of treatment: 1) In Step 1, to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustine has on you and your lymphoma compared to rituximab plus bendamustine alone. 2) In Step 2, to find out what effects,
Criteria:
Eligible Patients Must Have Untreated Mantle Cell Lymphoma
Keywords:
E1411, Lymphoma, Mantel Cell, Cancer, Hematology
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu